I don't like the non compete of 2591 in North America. I feel it limits the ability to sell rights of 2591 to anyone other than Acadia, which reduces the value of 2591 rights essentially and this is the jewel in the crown. What if Acadia develop trof in something like Parkinsons, this would take a massive market away from 2591, and to the detriment of patients if 2591 is clearly a better product, which it is looking to be with out doubt.
Best thing that could happen to us now is a big pharma take out Acadia and Neu in one hit.
Ann: Neuren and Acadia expand global partnership for trofinetide, page-55
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |